GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » 3-Year ROIIC %

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) 3-Year ROIIC % : -392.37% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Harvard Apparatus Regenerative Technology's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -392.37%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Harvard Apparatus Regenerative Technology's 3-Year ROIIC % or its related term are showing as below:

HRGN's 3-Year ROIIC % is ranked worse than
85.61% of 1418 companies
in the Biotechnology industry
Industry Median: -15.155 vs HRGN: -392.37

Harvard Apparatus Regenerative Technology 3-Year ROIIC % Historical Data

The historical data trend for Harvard Apparatus Regenerative Technology's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Apparatus Regenerative Technology 3-Year ROIIC % Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -399.68 3,922.62 237.01 1,246.67 -392.37

Harvard Apparatus Regenerative Technology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,246.67 - - - -392.37

Competitive Comparison of Harvard Apparatus Regenerative Technology's 3-Year ROIIC %

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's 3-Year ROIIC % falls into.



Harvard Apparatus Regenerative Technology 3-Year ROIIC % Calculation

Harvard Apparatus Regenerative Technology's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -8.99 (Dec. 2023) - -4.878 (Dec. 2020) )/( 1.88 (Dec. 2023) - 0.832 (Dec. 2020) )
=-4.112/1.048
=-392.37%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Harvard Apparatus Regenerative Technology 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Traded in Other Exchanges
N/A
Address
84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.
Executives
Junli He director C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling director 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc 10 percent owner C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard director 2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen director C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu officer: President C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr officer: Chief Financial Officer 14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green director, officer: See Remarks C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor officer: Chief Scientific Officer C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino officer: Interim VP of Finance C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez director 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge officer: See Remarks C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young director 60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang director C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li director C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746